Predicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium Eggerthella lenta
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Digoxin Dangers: A proportion of patients treated with digoxin, a cardiac glycoside used to treat heart function abnormalities, generate the inactive metabolite, dihydrodigoxin, resulting in poor efficacy. Haiser et al. (p. 295 ) examined a potential culprit responsible for this transformation—the actinobacterium, Eggerthella lenta —to probe the microbiota-digoxin interaction. Microbe growth was promoted by arginine, and differential expression analysis revealed a two-gene cardiac glycoside reductase ( cgr ) operon that was induced by digoxin in low arginine conditions. Not all strains of E. lenta could reduce digoxin and, when fecal samples from healthy people were tested, a spectrum of digoxin inactivation was detected. When the digoxin-reducing strain of E. lenta was given to germ-free mice that were fed a high-protein (that is, high-arginine) diet, digoxin levels stayed high in serum, and drug inactivation was suppressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Notably, the cgr ratio could be used to effectively discriminate microbial communities exhibiting low versus high digoxin reduction (Fig. 5).”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [67]
The cited source says what the claim attributes to it.
In the citing paper
“The amino acid arginine prevents digoxin inactivation by E. lenta in vitro, decreasing the expression and activity of the genes responsible (the cgr operon)67.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [67]
The cited source says what the claim attributes to it.
In the citing paper
“Because the intestine is a major site for drug metabolism (both by cytochrome P-450 enzymes in intestinal epithelial cells and by the gut microbiome87)”
From Microfluidic Organ-on-a-Chip Models of Human Intestine (2018) · cites this paper as [87]
The cited source says what the claim attributes to it.
In the citing paper
“Taken together, this functional metabolic repertoire includes the capacity for clinically relevant activation (e.g., sulfasalazine) (Peppercorn and Goldman, 1972b), reactivation (e.g., irinotecan/SN-38) (Wallace et al., 2010), and detoxification (e.g., digoxin) (Haiser et al., 2013) of xenobiotics with broad implications for drug action and toxicity (see Table 1).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Haiser et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“was inducible by the drug it metabolizes (Haiser et al., 2013).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Haiser et al., 2013
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primer3—new capabilities and interfaces
Untergasser, A., Cutcutache, I., Koressaar, T., Ye, J., Faircloth, B. C., Remm, M., & Rozen, S. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks596 · Cited by 9,461
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Versatile and open software for comparing large genomes
Kurtz, S., Phillippy, A., Delcher, A. L., Smoot, M., Shumway, M., Antonescu, C., & Salzberg, S. L. (2004) · Genome Biology · doi:10.1186/gb-2004-5-2-r12 · Cited by 5,254
Breitling, R., Armengaud, P., Amtmann, A., & Herzyk, P. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.055 · Cited by 1,496
Isolation of a Bacterium That Reductively Dechlorinates Tetrachloroethene to Ethene
Maymó-Gatell, X., Chien, Y.-T., Gossett, J. M., & Zinder, S. H. (1997) · Science · doi:10.1126/science.276.5318.1568 · Cited by 1,125
Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., et al. (2010) · Science · doi:10.1126/science.1191175 · Cited by 1,080
SSAHA: A Fast Search Method for Large DNA Databases
Ning, Z., Cox, A. J., & Mullikin, J. C. (2001) · Genome Research · doi:10.1101/gr.194201 · Cited by 965
Xenobiotics shape the physiology and gene expression of the active human gut microbiome
Maurice, C. F., Haiser, H. J., & Turnbaugh, P. J. (2013) · Cell · doi:10.1016/j.cell.2012.10.052 · Cited by 811
A Catalog of Reference Genomes from the Human Microbiome
The Human Microbiome Jumpstart Reference Strains Consortium, Nelson, K. E., Weinstock, G. M., Highlander, S. K., Worley, K. C., Creasy, H. H., Wortman, J. R., Rusch, D. B., Mitreva, M., Sodergren, E., et al. (2010) · Science · doi:10.1126/science.1183605 · Cited by 702
Inactivation of Digoxin by the Gut Flora: Reversal by Antibiotic Therapy
Lindenbaum, J., Rund, D. G., Butler, V. P., Tse-Eng, D., & Saha, J. R. (1981) · New England Journal of Medicine · doi:10.1056/nejm198110013051403 · Cited by 423
Cited by
Items 101–200 of 704
Linking microbiota to human diseases: a systems biology perspective
Wu, H., Tremaroli, V., & Bäckhed, F. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.09.011 · Cited by 150
“Another example of the effects of microbial metabolism on therapeutic drugs is the inactivation of the cardiac drug digoxin by the gut microbe Eggerthella lenta, which can reduce digoxin to its inactive metabolite dihydrodigoxin [123].”
BackgroundDrug–gut microbiota interactions: implications for neuropharmacology
Walsh, J., Griffin, B. T., Clarke, G., & Hyland, N. P. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14366 · Cited by 149
“The amino acid arginine has been shown to inhibit the Eggerthella lenta-encoding cgr operon, previously identified as essential for the microbiota-mediated reduction of the cardiac glycoside, digoxin (Haiser et al., 2013).”
BackgroundStrain-level epidemiology of microbial communities and the human microbiome
Yan, Y., Nguyen, L. H., Franzosa, E. A., & Huttenhower, C. (2020) · Genome Medicine · doi:10.1186/s13073-020-00765-y · Cited by 166
“In a very few cases to date, strain variants within microbial communities have been identified via analogous differences in metatranscriptomic gene expression quantification, such as strain-specific variation in Eggerthella lenta metabolism of the cardiac drug digoxin [49].”
BackgroundDark matter in host-microbiome metabolomics: Tackling the unknowns–A review
Peisl, B. Y. L., Schymanski, E. L., & Wilmes, P. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2017.12.034 · Cited by 146
Koppel, N., Bisanz, J. E., Pandelia, M.-E., Turnbaugh, P. J., & Balskus, E. P. (2018) · eLife · doi:10.7554/elife.33953 · Cited by 145
“RNA sequencing (Haiser et al., 2013) demonstrated that the cgr operon (cgr1 and cgr2) is highly upregulated (>165 fold) in response to digoxin, whereas cac4 is not significantly induced (1.3-fold change relative to vehicle controls, p=0.83) (Figure 1E).”
BackgroundMethodResultInfluentialSelf-citationAbdollahi‐Roodsaz, S., Abramson, S. B., & Scher, J. U. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.68 · Cited by 150
Population Genetics in the Human Microbiome
Garud, N. R., & Pollard, K. S. (2020) · Trends in Genetics · doi:10.1016/j.tig.2019.10.010 · Cited by 141
“sequencing [132] or metagenomic analysis (e.”
The Impact of the Gut Microbiota on Drug Metabolism and Clinical Outcome.
Enright, E. F., Gahan, C. G. M., Joyce, S. A., & Griffin, B. T. (2016) · PubMed · Cited by 202
Gawalko, M. M., Agbaedeng, T. A., Saljic, A., Müller, D. N., Wilck, N., Schnabel, R. B., Penders, J., Rienstra, M., Gelder, I. C. V., Jespersen, T., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab292 · Cited by 159
Exploring and Understanding the Biochemical Diversity of the Human Microbiota
Koppel, N., & Balskus, E. P. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2015.12.008 · Cited by 154
Self-citationMDAD: A Special Resource for Microbe-Drug Associations
Sun, Y., Zhang, D., Cai, S., Ming, Z., Li, J., & Chen, X. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00424 · Cited by 153
“For instance, the disorder of human microbiota can inactivate pharmaceuticals (Haiser et al., 2013) or increase the risk of cardiovascular diseases (Koeth et al.”
BackgroundMetatranscriptomics for the Human Microbiome and Microbial Community Functional Profiling
Zhang, Y., Thompson, K. N., Branck, T. A., Yan, Y., Nguyen, L. H., Franzosa, E. A., & Huttenhower, C. (2021) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-031121-103035 · Cited by 168
Microbial metabolites in health and disease: Navigating the unknown in search of function
Martinez, K. B., Leone, V., & Chang, E. B. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.752899 · Cited by 132
On the road to strain-resolved comparative metagenomics
Segata, N. (2018) · mSystems · doi:10.1128/msystems.00190-17 · Cited by 127
“…of the human microbiome is growing but remains anecdotal; some but not all intestinal strains of Eggerthella lenta can inactivate a cardiac drug (5), some subtypes of Prevotella copri are associated with increased risk for rheumatoid arthritis (6) whereas others are associated with healthy and…”
BackgroundMetagenomics and novel gene discovery: Promise and potential for novel therapeutics
Culligan, E. P., Sleator, R. D., Marchesi, J. R., & Hill, C. (2013) · Virulence · doi:10.4161/viru.27208 · Cited by 163
“Furthermore, mice fed a high protein diet had increased serum and urine digoxin indicating a reduction in digoxin inactivation, likely through increased dietary arginine.(93) Such studies open up new avenues for future therapeutic strategies.”
BackgroundHost and gut bacteria share metabolic pathways for anti-cancer drug metabolism
Spanogiannopoulos, P., Kyaw, T. S., Guthrie, B. G. H., Bradley, P. H., Lee, J. V., Melamed, J., Malig, Y. N. A., Lam, K. N., Gempis, D., Sandy, M., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01226-5 · Cited by 132
Self-citationMicrobial transmission in the social microbiome and host health and disease
Sarkar, A., McInroy, C. J. A., Harty, S., Raulo, A., Ibata, N. G. O., Valles‐Colomer, M., Johnson, K. V. ‐., Brito, I., Henrich, J., Archie, E. A., et al. (2024) · Cell · doi:10.1016/j.cell.2023.12.014 · Cited by 152
Velmurugan, G., Ramprasath, T., Swaminathan, K., Mithieux, G., Rajendhran, J., Dhivakar, M., Ayothi, P., Babu, D. D. V., Thumburaj, L. J., Freddy, A. J., et al. (2017) · Genome biology · doi:10.1186/s13059-016-1134-6 · Cited by 145
Models for drug absorption from the small intestine: where are we and where are we going?
Billat, P.-A., Roger, E., Faure, S., & Lagarce, F. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.007 · Cited by 125
Toxicomicrobiomics: The Human Microbiome vs. Pharmaceutical, Dietary, and Environmental Xenobiotics
Abdelsalam, N. A., Ramadan, A. T., ElRakaiby, M. T., & Aziz, R. K. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00390 · Cited by 122
Towards a mechanistic understanding of reciprocal drug–microbiome interactions
Zimmermann, M., Patil, K. R., Typas, A., & Maier, L. (2021) · Molecular Systems Biology · doi:10.15252/msb.202010116 · Cited by 121
“…differences in the communities’ drug-metabolizing capacity (Zimmermann et al , 2019b) (Fig 2), which are corroborated by differences in the drug-metabolizing potential for different bacterial species and strains (Lindenbaum et al , 1981; Haiser et al , 2013; Zimmermann et al , 2019b).”
InfluentialAutoimmune host–microbiota interactions at barrier sites and beyond
Ruff, W. E., & Kriegel, M. A. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.02.006 · Cited by 121
“The cardiac drug digoxin, however, was recently shown to be inactivated by the specific strain Eggerthella lenta DSM2243, whereas other strains were incapable of inactivating digoxin [82].”
BackgroundTargeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs
Feng, W., Liu, J., Ao, H., Yue, S., & Peng, C. (2020) · Theranostics · doi:10.7150/thno.47289 · Cited by 121
Xenobiotics: Interaction with the Intestinal Microflora
Lu, K., Mahbub, R., & Fox, J. G. (2015) · ILAR Journal · doi:10.1093/ilar/ilv018 · Cited by 117
“A recent study has elucidated a mechanism involved in the metabolism of digoxin by showing the upregulation of a two-gene cytochrome-encoding operon in E. lenta that was co-administered with digoxin (Haiser et al. 2013).”
BackgroundGut Microbiome and Response to Cardiovascular Drugs
Tuteja, S., & Ferguson, J. F. (2019) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.119.002314 · Cited by 134
The potential of tailoring the gut microbiome to prevent and treat cardiometabolic disease
Chakaroun, R., Olsson, L. M., & Bäckhed, F. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00771-0 · Cited by 139
Precision Medicine Goes Microscopic: Engineering the Microbiome to Improve Drug Outcomes
Lam, K. N., Alexander, M., & Turnbaugh, P. J. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.06.011 · Cited by 126
Self-citationNishijima, S., Nagata, N., Kiguchi, Y., Kojima, Y., Miyoshi‐Akiyama, T., Kimura, M., Ohsugi, M., Ueki, K., Oka, S., Mizokami, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32832-w · Cited by 138
Cardiometabolic health, diet and the gut microbiome: a meta-omics perspective
Valles-Colomer, M., Menni, C., Berry, S. E., Valdes, A. M., Spector, T. D., & Segata, N. (2023) · Nature Medicine · doi:10.1038/s41591-023-02260-4 · Cited by 114
Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response
Scher, J. U., Nayak, R. R., Úbeda, C., Turnbaugh, P. J., & Abramson, S. B. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0395-3 · Cited by 121
Self-citationFang, B., Li, J. W., Zhang, M., Ren, F., & Pang, G. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.11.001 · Cited by 121
Tsunoda, S. M., Gonzales, C., Jarmusch, A. K., Momper, J. D., & JOSEPH, D. R. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01032-y · Cited by 129
“[19] later determined that a two-gene cytochrome-encoding operon (now referred to as cardiac glycoside reductase) was upregulated > 100-fold in the presence of digoxin in certain E.”
BackgroundInfluentialReynoso-García, J., Miranda-Santiago, A. E., Meléndez-Vázquez, N. M., Acosta-Pagán, K. T., Rosado, M. R. S., Díaz-Rivera, J., Rosado-Quiñones, A. M., Acevedo-Márquez, L., Cruz-Roldán, L., Tosado-Rodríguez, E. L., et al. (2022) · Frontiers in Systems Biology · doi:10.3389/fsysb.2022.951403 · Cited by 125
“which leads to a decreased target affinity of the drug (Haiser et al., 2013).”
BackgroundBess, E. N., Bisanz, J. E., Yarza, F., Bustion, A. E., Rich, B. E., Li, X., Kitamura, S., Waligurski, E., Ang, Q. Y., Alba, D., et al. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0596-1 · Cited by 109
Self-citationGut microbiota as an “invisible organ” that modulates the function of drugs
Li, X., Liu, L., Cao, Z., Li, W., Li, H., Lu, C. C., Yang, X., & Liu, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109653 · Cited by 115
Commensals, probiotics and pathogens in the C aenorhabditis elegans model
Clark, L. C., & Hodgkin, J. (2013) · Cellular Microbiology · doi:10.1111/cmi.12234 · Cited by 117
“The importance of the gut microbiota in pharmaceutical interventions is underlined by the recent discovery that the cytochrome-encoding cyr1 and cyr2 genes of human gut bacterium Eggerthella lenta are upregulated in the presence of cardiac drug digoxin, leading to inactivation of the drug in patients (Haiser et al., 2…”
BackgroundSystems biology of host–microbe metabolomics
Heinken, A., & Thiele, I. (2015) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1301 · Cited by 101
“166 Using a computational framework, the transformation of drugs and xeno-biotics (e.g., antibiotics) can be predicted and linked to specific species.”
BackgroundWang, X., Shen, M., Zhou, J., & Jin, Y. (2018) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2018.11.010 · Cited by 114
Mamic, P., Chaikijurajai, T., & Tang, W. H. W. (2020) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.12.001 · Cited by 107
Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism
Dikeocha, I. J., Al‐Kabsi, A. M., Miftahussurur, M., & Alshawsh, M. A. (2022) · The FASEB Journal · doi:10.1096/fj.202101986r · Cited by 114
Determining Microbial Products and Identifying Molecular Targets in the Human Microbiome
Joice, R., Yasuda, K., Shafquat, A., Morgan, X. C., & Huttenhower, C. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.10.003 · Cited by 100
“Gut microbiota have also been shown to modify drugs consumed by the host, potentially altering drug response (Haiser et al., 2013; Wallace et al., 2010).”
BackgroundBidirectional interactions between indomethacin and the murine intestinal microbiota
Liang, X., Bittinger, K., Li, X., Abernethy, D. R., Bushman, F. D., & FitzGerald, G. A. (2015) · eLife · doi:10.7554/elife.08973 · Cited by 99
“, 2009), and digoxin is directly inactivated by the gut Actinobacterium Eggerthella lenta (Haiser et al., 2013; 2014).”
BackgroundGut-Heart Axis: The Role of Gut Microbiota and Metabolites in Heart Failure
Snelson, M., Muralitharan, R. R., Liu, C., Markó, L., Forslund, S. K., Marques, F. Z., & Tang, W. H. W. (2025) · Circulation Research · doi:10.1161/circresaha.125.325516 · Cited by 126
Transformation of the Anticancer Drug Doxorubicin in the Human Gut Microbiome
Yan, A., Culp, E., Perry, J., Lau, J. T., MacNeil, L. T., Surette, M. G., & Wright, G. D. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00166 · Cited by 97
Su, J., Li, D., Chen, Q., Li, M., Su, L., Luo, T. L., Liang, D., Lai, G., Shuai, O., Jiao, C., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03099 · Cited by 108
“This is mainly attributed to their intrinsic capcities of drug metabolism and the influence on host metabolizing homeostasis (Haiser et al., 2013; Wilson and Nicholson, 2017).”
BackgroundRoles of the gut microbiome in weight management
Carmody, R. N., & Bisanz, J. E. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00888-0 · Cited by 118
Houghton, D., Hardy, T., Stewart, C., Errington, L., Day, C. P., Trenell, M. I., & Avery, L. (2018) · Diabetologia · doi:10.1007/s00125-018-4632-0 · Cited by 94
“The gut microbiota influences energy harvest [12], blood glucose [13] and the effectiveness of pharmacotherapy [14].”
BackgroundSu, J., Su, L., Li, D. X., Shuai, O., Zhang, Y., Liang, H., Jiao, C., Xu, Z., Lai, Y. R., & Xie, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01765 · Cited by 99
“On the other hand, increasing evidence highlights the cardinal role of gut microbiota in tumour genesis (14, 15) and that in the outcomes of chemotherapy (16) and immunotherapy (17, 18), due to their intrinsic capacity of drug metabolism and the influence on host metabolizing homeostasis (19, 20).”
BackgroundMatušková, Z., Anzenbacherová, E., Večeřa, R., Tlaskalová‐Hogenová, H., Kolář, M., & Anzenbacher, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087150 · Cited by 97
“The importance of both, human and commensal microbiota components in drug efficacy and toxicity was recently documented and pointed out Haiser et al., 2013 [5].”
BackgroundDearing, M. D., & Kohl, K. D. (2017) · Integrative and Comparative Biology · doi:10.1093/icb/icx020 · Cited by 97
Gut microbiome and lipid metabolism: from associations to mechanisms
Wang, Z., Koonen, D., Hofker, M., & Fu, J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000308 · Cited by 93
Systematically investigating the impact of medication on the gut microbiome
Maier, L., & Typas, A. (2017) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.11.001 · Cited by 98
The gut microbiome and hypertension
Pevsner‐Fischer, M., Blacher, E., Tatirovsky, E., Ben‐Dov, I. Z., & Elinav, E. (2016) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000293 · Cited by 93
Metabolic functions of the human gut microbiota: the role of metalloenzymes
Rajakovich, L. J., & Balskus, E. P. (2019) · Natural Product Reports · doi:10.1039/c8np00074c · Cited by 96
Self-citationEnsembling graph attention networks for human microbe–drug association prediction
Long, Y., Wu, M., Liu, Y., Kwoh, C. K., Luo, J., & Li, X. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa891 · Cited by 104
Complexities of Gut Microbiome Dysbiosis in the Context of HIV Infection and Antiretroviral Therapy
Li, X., Armstrong, A., Neff, C. P., Shaffer, M., Lozupone, C., & Palmer, B. E. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.363 · Cited by 105
“Gut microbiome composition influences the response to cancer therapy,(47) the toxicity of acetaminophen,(48) and the activity of cardiac drugs.(49) As a result, baseline differences in the microbiome of HIV-infected individuals may affect both the effectiveness of therapy as well as the potential restoration of a heal…”
BackgroundMechanisms of gastrointestinal microflora on drug metabolism in clinical practice
Sun, C., Chen, L., & Shen, Z. (2019) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2019.09.011 · Cited by 97
“In recent years, a large number of studies on drug metabolism mechanisms have proved that the intestinal microbiota possesses a variety of metabolic activities that are able to modulate the fate of more than 30 approved drugs and their bioavailability (Okuda et al., 1998; Clayton et al., 2009; Haiser et al., 2014).”
Microbiome epidemiology and association studies in human health
VanEvery, H., Franzosa, E. A., Nguyen, L. H., & Huttenhower, C. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00529-x · Cited by 94
A framework for microbiome science in public health
Wilkinson, J. E., Franzosa, E. A., Everett, C., Li, C., trainees, H. R. A., Bae, S., Berzansky, I., Bhosle, A., Bjørnevik, K., Brennan, C. A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01258-0 · Cited by 99
Hameed, A. S. S., Rawat, P. S., Meng, X., & Liu, W. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107576 · Cited by 97
Bile acid oxidation byEggerthella lentastrains C592 and DSM 2243T
Harris, S. C., Devendran, S., Méndez–García, C., Mythen, S. M., Wright, C. L., Fields, C. J., Hernandez, A. G., Cann, I., Hylemon, P. B., & Ridlon, J. M. (2018) · Gut Microbes · doi:10.1080/19490976.2018.1458180 · Cited by 135
Graph2MDA: a multi-modal variational graph embedding model for predicting microbe–drug associations
Deng, L., Huang, Y., Liu, X., & Liu, H. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab792 · Cited by 105
Microbiome and metabolome data integration provides insight into health and disease
Shaffer, M., Armstrong, A. J. S., Phelan, V. V., Reisdorph, N. A., & Lozupone, C. (2017) · Translational research · doi:10.1016/j.trsl.2017.07.001 · Cited by 96
Circulating Metabolites Originating from Gut Microbiota Control Endothelial Cell Function
Amedei, A., & Morbidelli, L. (2019) · Molecules · doi:10.3390/molecules24213992 · Cited by 90
Potential roles of gut microbes in biotransformation of natural products: An overview
Zhao, Y., Zhong, X., Yan, J., Sun, C., Zhao, X., & Wang, X. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.956378 · Cited by 107
The Implication of the Gut Microbiome in Heart Failure
Lupu, V. V., Răileanu, A. A., Mihai, C. M., Morariu, I. D., Lupu, A., Stârcea, I. M., Frăsinariu, O. E., Mocanu, A., Dragan, F., & Fotea, S. (2023) · Cells · doi:10.3390/cells12081158 · Cited by 98
The functional impact of the intestinal microbiome on mucosal immunity and systemic autoimmunity
Longman, R. S., & Littman, D. R. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000190 · Cited by 82
Predicting drug-microbiome interactions with machine learning
McCoubrey, L. E., Gaisford, S., Orlu, M., & Basit, A. W. (2022) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107797 · Cited by 79
Personalized medicine—concepts, technologies, and applications in inflammatory skin diseases
Litman, T. (2019) · Apmis · doi:10.1111/apm.12934 · Cited by 95
Dietary- and host-derived metabolites are used by diverse gut bacteria for anaerobic respiration
Little, A. S., Younker, I. T., Schechter, M. S., Bernardino, P. N., Méheust, R., Stemczynski, J., Scorza, K., Mullowney, M. W., Sharan, D., Waligurski, E., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-023-01560-2 · Cited by 80
Impacts of the Human Gut Microbiome on Therapeutics
Vázquez-Baeza, Y., Callewaert, C., Debelius, J., Hyde, E., Marotz, C., Morton, J. T., Swafford, A., Vrbanac, A., Dorrestein, P. C., & Knight, R. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-042017-031849 · Cited by 79
High-resolution characterization of the human microbiome
Noecker, C., McNally, C. P., Eng, A., & Borenstein, E. (2017) · Translational Research · doi:10.1016/j.trsl.2016.07.012 · Cited by 79
“Careful differentiation of strains can also inform clinical decision making by, for example, providing valuable insights as to whether a patient will respond to the heart failure drug digoxin.(14) Accurate detection of lowabundance species is similarly essential as such rare species may still play important roles in v…”
BackgroundMaini Rekdal, V., Nol Bernadino, P., Luescher, M. U., Kiamehr, S., Le, C., Bisanz, J. E., Turnbaugh, P. J., Bess, E. N., & Balskus, E. P. (2020) · eLife · doi:10.7554/elife.50845 · Cited by 75
“Gut microbial activities can also vary significantly between individuals, affecting the toxicity and efficacy of drugs (Zimmermann et al., 2019; Koppel et al., 2018; Gopalakrishnan et al., 2018; Wallace et al., 2010; Haiser et al., 2013), susceptibility to infection (Buffie et al.”
BackgroundSelf-citationBacterial Peptidoglycan Fragments Differentially Regulate Innate Immune Signaling
Bersch, K. L., DeMeester, K. E., Zagani, R., Chen, S., Wodzanowski, K. A., Liu, S., Mashayekh, S., Reinecker, H., & Grimes, C. L. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00200 · Cited by 90
Sharma, A. K., Jaiswal, S. K., Chaudhary, N., & Sharma, V. K. (2017) · Scientific Reports · doi:10.1038/s41598-017-10203-6 · Cited by 80
Soto-Perez, P., Bisanz, J. E., Berry, J. D., Lam, K. N., Bondy‐Denomy, J., & Turnbaugh, P. J. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.08.008 · Cited by 69
“, 2018); (2) broad impact on the metabolism of drugs (Haiser et al., 2013; Koppel et al., 2018), dietary bioactives (Bess et al.”
BackgroundSelf-citationEmerging approaches to polypharmacy among older adults
Mehta, R. S., Kochar, B. D., Kennelty, K. A., Ernst, M. E., & Chan, A. T. (2021) · Nature Aging · doi:10.1038/s43587-021-00045-3 · Cited by 84
Alterations in the intestinal microbiome associated with PCOS affect the clinical phenotype
Wang, L., Zhou, J., Gober, H.-J., Leung, W. T., Huang, Z., Pan, X., Li, C., Zhang, N., & Wang, L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110958 · Cited by 87
Tesei, D., Jewczynko, A., Lynch, A., & Urbaniak, C. (2022) · Life · doi:10.3390/life12040495 · Cited by 88
A meta-analysis study of the robustness and universality of gut microbiome-metabolome associations
Muller, E., Algavi, Y. M., & Borenstein, E. (2021) · Microbiome · doi:10.1186/s40168-021-01149-z · Cited by 85
Bringing microbiome-drug interaction research into the clinic
Guthrie, L., & Kelly, L. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.05.009 · Cited by 83
“To datemetabolic phenotyping studies ofmicrobe-drug interactions pairing DNA or RNA high throughput sequencing with metabolomics reveal that the level of gut microbiome complexity linked to drug metabolism varies between drugs [45,46,58].”
BackgroundChallenges and opportunities in sharing microbiome data and analyses
Huttenhower, C., Finn, R. D., & McHardy, A. C. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01484-x · Cited by 79
Gut bacterial dysbiosis in children with intractable epilepsy
Lee, K., Kim, N., Shim, J. O., & Kim, G.-H. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010005 · Cited by 70
“Among them, Eggerthella lenta has been reported to inhibit digoxin, a cardiac glycoside, through the cardiac glycoside reductase operon’s products, and the quantification of this operon in the gut microbiome could predict inter-individual variation in the pharmacokinetics of digoxin [38].”
BackgroundDong, H.-L., Zhang, S., Chen, Z.-H., Tao, H., Li, X., Qiu, J., Cui, W., Sima, Y., Cui, W.-Z., & Xu, S.-Q. (2018) · RSC Advances · doi:10.1039/c8ra04627a · Cited by 90
Gut microbiome and cardiovascular disease
Zhao, Y., & Wang, Z. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000720 · Cited by 77
Whidbey, C., Sadler, N. C., Nair, R. N., Volk, R. F., DeLeon, A. J., Bramer, L. M., Fansler, S. J., Hansen, J. R., Shukla, A. K., Jansson, J. K., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b09668 · Cited by 70
The Gut Microbiome as a Therapeutic Target for Cognitive Impairment
Sun, Y., Baptista, L. C., Roberts, L. M., Jumbo-Lucioni, P., McMahon, L. L., Buford, T. W., & Carter, C. S. (2020) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glz281 · Cited by 70
“Furthermore, gut microbiota also provides a source of energy biogenesis (8), regulating biosynthesis of vitamins and neurotransmitters (9), metabolizing bile salts (10), reacting or modifying specific drugs, and eliminating exogenous toxins (11).”
BackgroundSimpson, J. B., Walker, M. E., Sekela, J. J., Ivey, S. M., Jariwala, P. B., Storch, C. M., Kowalewski, M. E., Graboski, A. L., Lietzan, A. D., Walton, W. G., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.04.018 · Cited by 78
Ahmed, T., Auble, D., Berkley, J. A., Black, R., Ahern, P. P., Hossain, M., Hsieh, A., Ireen, S., Arabi, M., & Gordon, J. I. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12487 · Cited by 69
Emulating Host-Microbiome Ecosystem of Human Gastrointestinal Tract in Vitro
Park, G.-S., Park, M. H., Shin, W., Zhao, C., Sheikh, S., Oh, S. J., & Kim, H. J. (2017) · Stem Cell Reviews and Reports · doi:10.1007/s12015-017-9739-z · Cited by 73
Antibiotics may increase triazine herbicide exposure risk via disturbing gut microbiota
Zhan, J., Liang, Y., Liu, D., Ma, X., Li, P., Liu, C., Liu, X., Wang, P., & Zhou, Z. (2018) · Microbiome · doi:10.1186/s40168-018-0602-5 · Cited by 73
Bile acids at the cross-roads of gut microbiome–host cardiometabolic interactions
Ryan, P. M., Stanton, C., & Caplice, N. M. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0299-9 · Cited by 71
“Translational outlook Over the past several decades, a multiplicity of clinically relevant functions of the microbiome have become evident including inter alia prevention of enteral colonization by pathogens, education of the host immune system, modulation of host metabolism, bile acid deconjugation and caloric salvag…”
BackgroundStrain diversity in the microbiome: Lessons from Bacteroides fragilis
Carrow, H. C., Batachari, L. E., & Chu, H. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1009056 · Cited by 73
“Strains of gut commensal Eggerthella lenta show differences in the ability to inactivate the cardiac drug digoxin, which can affect clinical outcomes [43].”
BackgroundMicrobial Determinants of Biochemical Individuality and Their Impact on Toxicology and Pharmacology
Patterson, A. D., & Turnbaugh, P. J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.07.002 · Cited by 66
“Recent studies have elucidated the inactivation of the cardiac drug digoxin by the gut Actinobacterium Eggerthella lenta (Haiser et al., 2013), a topic that has been discussed extensively elsewhere (Haiser et al., 2014).”
InfluentialSelf-citationMicrobial exposure and human health
Sharma, A., & Gilbert, J. A. (2018) · Current Opinion in Microbiology · doi:10.1016/j.mib.2018.08.003 · Cited by 72
Hatton, G. B., Madla, C. M., Rabbie, S. C., & Basit, A. W. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.06.054 · Cited by 71
The importance of the microbiome in pediatrics and pediatric infectious diseases
Gaufin, T., Tobin, N. H., & Aldrovandi, G. M. (2017) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000576 · Cited by 76
Cardiovascular Pharmacogenomics: Expectations and Practical Benefits
Turner, R. M., & Pirmohamed, M. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.234 · Cited by 68
A Genomic Toolkit for the Mechanistic Dissection of Intractable Human Gut Bacteria
Bisanz, J. E., Soto-Perez, P., Noecker, C., Aksenov, A. A., Lam, K. N., Kenney, G. E., Bess, E. N., Haiser, H. J., Kyaw, T. S., Yu, F. B., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.006 · Cited by 62
“Coriobacteriia catalyze a wide range of biotransformations of drugs (Haiser et al., 2013; Koppel et al., 2018), dietary phytochemicals (Bess et al.”
BackgroundSelf-citationThe Microbiota, the Immune System and the Allograft
Alegre, M.-L., Mannon, R. B., & Mannon, P. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12760 · Cited by 69
“These strains could metabolize digoxin into inactive hydrodigoxin but their metabolic activity was inhibited by proteins from the diet, resulting in toxic rather than therapeutic drug levels (115).”
Background
Metadata
- Authors
- Haiser, H. J., Gootenberg, D. B., Chatman, K., Sirasani, G., Balskus, E. P., & Turnbaugh, P. J.
- Affiliations
- Harvard University (US)
- Corresponding author
- Turnbaugh, Peter J.
- Venue
- Science
- Published
- 2013-07-19
- Volume
- 341
- Issue
- 6143
- Pages
- 295-298
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3736355
- OpenAlex
- W2161185495
- Cited by
- 704
- References
- 25
- Citations by year
- 2026: 66 · 2025: 58 · 2024: 64 · 2023: 65 · 2022: 54 · 2021: 59 · 2020: 77 · 2019: 56 · 2018: 56 · 2017: 41 · 2016: 31 · 2015: 31 · 2014: 38 · 2013: 8
- FWCI
- 39.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (112991_1)
- National Institute of General Medical Sciences (P50GM068763)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034854)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Eggerthella lenta, digoxin, drug inactivation, gut microbiota, cytochrome P450, gnotobiotic mice, dietary protein, pharmacokinetics, cardiovascular drugs, human-microbe interactions
- MeSH terms
- Animals, Arginine, Cytochromes, Dietary Proteins, Digoxin, Feces, Germ-Free Life, Humans, Mice, Inbred Strains, Operon, Gene Expression Regulation, Bacterial, Actinobacteria, Gastrointestinal Tract, Mice, Metagenome, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.